Changes in skeletal muscle pO2 after administration of anti-TNF alpha-antibody in patients with severe sepsis: comparison to interleukin-6 serum levels, APACHE II, and Elebute scores

• Published in: Shock (Augusta, Ga.) Vol. 1; no. 4; p. 246
• Main Authors: Boekstegers, P, Weidenhöfer, S, Zell, R, Holler, E, Kapsner, T, Redl, H, Schlag, G, Kaul, M, Kempeni, J, Werdan, K
• Format: Journal Article
• Language: English
• Published: United States 01.04.1994
• Subjects: Adult; Aged; Antibodies, Monoclonal - administration & dosage; Female; Humans; Interleukin-6 - blood; Male; Middle Aged; Muscle, Skeletal - metabolism; Oxygen Consumption; Sepsis - immunology; Sepsis - metabolism; Sepsis - therapy; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - immunology; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 1073-2322
• DOI: 10.1097/00024382-199404000-00002

In 20 patients with severe sepsis, skeletal muscle pO2 was continuously measured in order to assess whether a decrease of skeletal muscle pO2 was accompanied by an improvement of sepsis after repeated administration of F(ab')2 fragments of a murine anti-TNF alpha-antibody. Abnormally high skeletal muscle pO2 decreased from 43.5 +/- 10.9 mmHg (day 0) to 36.4 +/- 10.1 mmHg within 24 h after the first administration of anti-TNF alpha-antibody (day 1, p = .006, n = 20) and remained at 34.6 +/- 7.7 mmHg thereafter (mean day 2-7, p = .004). The decrease of skeletal muscle pO2 within 24 h exceeded 5 mmHg (-7 to -19 mmHg) in 11 patients in contrast to nine patients (-4 to +4 mmHg). Only in the patients showing a decrease of skeletal muscle pO2 did sepsis improve as determined by Elebute score, APACHE II score, and interleukin-6 serum levels. The change of skeletal muscle pO2 within 24 h was associated with a change of interleukin-6 serum levels within 24 h (r = .5, n = 20), with a change of Elebute score (r = .7, n = 20) and of APACHE II score (r = .62). These data suggest that a decrease of skeletal muscle pO2 might be an early indicator of improvement of sepsis after administration of anti-TNF alpha-antibodies.